Fel d1 Monoclonal Antibodies for Rapid Allergy Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergies, such as immunotherapy, are time-consuming and have variable efficacy, posing risks and taking years to induce tolerance, while existing antibody therapies lack a rapid and reliable approach for preventing allergic responses.
Innovation Solution
Administration of allergen-specific monoclonal antibodies or antigen-binding fragments that bind to allergens like Fel d1 to prevent IgE crosslinking on mast cells, thereby blocking the release of inflammatory mediators and reducing allergic symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunotherapy is used to treat allergies, then tolerance to allergens is induced, but the treatment takes years and has variable efficacy
Solution Approach 1:
The patent applies preliminary action by administering pre-formed monoclonal antibodies that immediately bind to allergens before they can interact with IgE on mast cells. This eliminates the need for years of immunotherapy to induce tolerance, as the antibodies are already prepared and ready to block the allergic response pathway from the start of treatment.
Solution Approach 2:
The monoclonal antibodies serve as an intermediary substance that blocks the interaction between allergens and IgE receptors on mast cells. By introducing this intermediate agent, the patent creates a new therapeutic pathway that bypasses the slow process of immunotherapy-induced tolerance while reliably preventing allergic responses.
2Reliability
If existing antibody therapies are used to block allergen entry, then allergic responses are prevented, but the approaches lack rapid and reliable efficacy
Solution Approach 1:
The patent applies parameter changes by optimizing the monoclonal antibodies for high affinity binding to specific allergens (e.g., Fel d1) and engineering them with appropriate half-life characteristics. These parameter optimizations ensure that the antibodies remain at effective concentrations in the body and reliably block allergen-IgE interactions, achieving both rapid onset and sustained reliability.
Solution Approach 2:
The patent replaces the mechanical/chemical process of allergen processing and IgE sensitization (which takes years through immunotherapy) with a direct biological blocking mechanism using monoclonal antibodies. This substitution of the therapeutic mechanism enables immediate prevention of allergic responses without requiring the slow immunological reprogramming of traditional approaches.
3Ease of operation
If steroids and bronchial dilators are used to suppress immune activity and relieve symptoms, then allergic symptoms are managed, but the treatment does not prevent the underlying allergic response
Solution Approach 1:
The patent extracts and targets the specific pathological interaction between allergens and IgE on mast cells, separating this critical event from the broader downstream inflammatory cascade. By specifically blocking the initial allergen-IgE binding event, the treatment prevents the allergic response at its source rather than merely managing downstream symptoms, while avoiding the side effects of broad immune suppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide rapid relief from allergic symptoms, measured by improved patient-reported outcomes and reduced severity of symptoms such as sneezing, congestion, and asthma within weeks, offering a safer and more effective alternative to traditional immunotherapy.
Implementation Method 1
Administration of allergen-specific monoclonal antibodies or antigen-binding fragments that bind to allergens like Fel d1 to prevent IgE crosslinking on mast cells
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.